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Key signaling pathways in breast cancer 
based on somatic mutation data
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Mutation frequencies (%) in all tumors, 
or just within luminal (including HER2+) 
and TNBC subtypes.
Colors indicate tumor suppressors (blue), oncogenes (red), or mutant genes with unclear roles (purple),
and lighter shading marks pathway components in which somatic mutations have not been identified.
Top 21 most commonly mutated
genes in breast cancer
TP53 35 26 54
PIK3CA 34 44 8
GATA3 9 13 0
MAP3K1 8 11 0
MLL3 6 8 3
CDH1 6 8 2
USH2A 5 4 8
PTEN 3 3 3
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MAP2K4 3 4 1
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RB1 3 2 5
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PIK3R1 2 3 2
CTCF 2 2 1
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FOXA1 1 1 1
CDKN1B 1 1 0
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a Raloxifene is used for breast cancer prevention, not treatment, b mTOR inhibitor, 
c dual PI3K/mTOR inhibitor, d AKT inhibitor, e also inhibits VEGFR.
Tamoxifen
Raloxifenea
Fulvestrant
Megestrol
Toremifene
Anastrozole
Letrozole
Exemestane
Estradiol
Pertuzumab
Trastuzumab
T-DM1
Lapatinib
Neratinib
MM-121
Afatinib
Canertinib
Dacomitinib
IGF, IGF-1R
MEDI-573
Figitumumab
Linsitinib
Ganitumab
BMS-754807
Cixutumumab
Dalotuzumab
Everolimusb
BYL719
AZD8055b
BEZ235c
BGT226
BKM120
PX-866
Temsirolimusb
GDC-0941
GDC-0032
GDC-0068d
GDC-0980c
XL147
XL765c
PKI-587c
INK128b
MK2206b
PF-04691502c
INK1117
MEDI-575
Nintedanib
Olaratumab
Sunitinib
SorafenibBrivanib
Aflibercept
Axitinib
Bevacizumab
Motesanib
Ponatinib
Semaxanib
Vatalanib
Vandetanib 
Lenvatinib
Pazopanib
Cabozantinibe, Foretinibe,
Onartuzumab (MET)
AZD4547, BGJ398, Dovitinib,
E-3810e, HGS1036  (FGFR)
AUY922, Retaspimycin,
Tanespimycin (HSP90)
Ruxolitinib (JAK)
Denosumab (RANKL)
PARP
BMN-673
CEP-9722
E7016
INO-1001
MK4827
Olaparib
Rucaparib
Veliparib
TNBC
10%
20%
70%
HER2+
Luminal, 
non-HER2+
NCOA3
TNBC Triple-negative breast cancers are ER-PR-HER2- and show significant, 
but not complete, overlap with the basal-like subtype of breast cancer (which 
is defined by differentiation state and gene expression profile).
HER2+ breast cancers 
have luminal features 
and are characterized 
by ERBB2 gene 
amplification and 
overexpression leading 
to a dependency on 
HER2 signaling.
Luminal (non-HER2+)
tumors are typically 
estrogen receptor positive, 
displaying high ERα levels. 
These tumors are dependent 
on estrogen for growth and, 
therefore, respond to 
endocrine therapy.
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Breast cancer is the most commonly diagnosed cancer and the principle cause of cancer-related mortality in women worldwide. Breast tumors are highly heterogeneous and are 
classified based on: (1) histology into ductal or lobular carcinomas, (2) differentiation state/gene expression profiles into luminal and basal-like subtypes, and (3) the expression 
of estrogen and progesterone receptors and HER2 into ER+, HER2+, and ER−PR−HER2− (triple-negative breast cancer, TNBC) subtypes. HER2+ and ER+ tumors all have luminal 
features, whereas TNBCs show significant but not complete overlap with basal-like subtype. The categorization of breast tumors based on hormone receptor and HER2 status 
and the use of antihormonal and HER2-targeted therapy, respectively, are among the first examples for molecular-based classification and personalized cancer treatment that 
made a significant difference in clinical outcomes. The widespread use of mammograms has lead to increased diagnosis of early stage disease, including ductal carcinoma in 
situ (DCIS), which also contributed to a decrease in mortality rates. The pie chart in the adjacent figure shows frequencies of various clinically relevant breast cancer subtypes, 
and the top table summarizes the prognoses of these subtypes.
Systematic characterization of breast cancer genomes has identified somatic mutations in several key signaling pathways depicted in the adjacent figure. The top 21 genes 
with the most frequent nucleotide sequence changes are summarized in the middle table. The increased activities of these signaling pathways serve both as therapeutic targets 
and as biomarkers guiding the selection of patients who would most likely benefit from particular therapies. Current pathways and compounds used for rationally designed 
targeted therapy in breast cancer are listed in the bottom table.
Estrogen Receptor Alpha
The estrogen receptor alpha (ERα) nuclear hormone receptor, encoded by ESR1, is a ligand-dependent transcription factor. Upon estrogen binding, ERα directly and indirectly 
activates the expression of numerous genes. ERα’s activity is modulated by coactivators, including NCOA3. Whereas ERα is expressed in only a small subset of cells in normal 
breast epithelium, where it plays an important role in breast development and differentiation, 65%–70% of breast tumors display high ERα levels and estrogen dependency for 
growth. Therefore, these ER+ tumors respond to endocrine therapy. Several therapeutic approaches have been designed to modulate ER activity, including competitive antago-
nists, downregulators of ER protein levels, and inhibitors of the aromatase enzyme that produces estrogen.
HER2
HER2, encoded by the ERBB2 proto-oncogene, is a receptor tyrosine kinase (RTK) and a member of the epidermal growth factor receptor (EGFR) family. HER2 forms heterodim-
ers with all three other members of the EGFR family, yielding different complexes with different kinase activities and physiologic functions. ERBB2 is amplified and overexpressed 
in ~20%–25% of breast carcinomas, leading to their dependency on HER2 signaling. The number of HER2-targeted therapies has increased significantly in recent years; these 
therapies include simple or drug-conjugated antibodies and small-molecule inhibitors of RTK activity specific for HER2 or broader for additional EGFR family members. These 
therapies have significantly improved disease-specific and overall survival of patients with HER2+ breast cancer.
PI3K, AKT, and PTEN
PIK3CA encodes the 110 kDa catalytic subunit of a class I phosphatidylinositol 3-kinase (PI3K). The 85 kDa regulatory subunit acts as an adaptor and mediates the activation 
of PI3K by RTKs and other kinases. PI3K phosphorylates phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 plays a key role in regulating the activity of signaling cascades involved in cell growth, survival, proliferation, metabolism, motility, and morphology by 
recruiting PH-domain-containing proteins, including AKT1 and PDPK1, to the cell membrane. A large fraction of human malignancies, including ~30% of breast carcinomas, 
have somatic mutations in PIK3CA leading to constitutive activation of the downstream signaling pathway. The activity of PI3K is antagonized by the PTEN tumor suppressor. 
PTEN is a dual-specificity phosphatase that dephosphorylates PIP3, leading to inhibition of AKT kinase activity, and can also antagonize the MAP kinase pathway via its protein 
phosphatase function. Germline mutations in PTEN play a role in Cowden disease and Bannayan-Zonana syndrome leading to increased cancer risk. Somatic inactivation of 
PTEN is common in a wide range of human cancers, including breast cancer. Approximately 50% of breast carcinomas have an activated PI3K/AKT pathway due to mutations 
in one of its components, making this kinase signaling cascade an attractive therapeutic target. Small-molecule inhibitors targeting PI3K, AKT, mTOR, or their combination are 
in various phases of clinical development.
MAP3K1, MAP2K4, and JNK1
MAP3K1 is a mitogen-activated protein kinase (MAPK) kinase kinase that regulates the ERK and JNK MAPK pathways, the NF-κB transcription factor, and the p300 tran-
scriptional coactivator. MAP2K4 is another member of the MAPK-JNK signaling pathway functioning between MAP3K1 and JNK. Frequent somatic mutations in MAP3K1 and 
MAP2K4 have recently been reported in breast cancer, identifying MAPK-JNK signaling as a key pathway in breast cancer.
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